Lonza, the pharmaceutical, health care and life science industries supplier, has reported solid first quarter 2013 results, with the specialty ingredients market segment putting in a notably “good performance”.
All growth projects in this segment were reported as being on track, while preservative and specialty ingredients sales were “tracking slightly ahead of target”. Lonza recently introduced new products for anti-ageing and anti-acne, as well as a natural preservative that provides a broad spectrum anti-microbial effect in cosmetic products, along with fragrance enhancement.
Richard Ridinger, CEO of Lonza, said: “Earlier this year, we announced significant changes to our organisation; aligning ourselves directly with markets we serve. I am pleased to report the newly focused organisation is taking hold while delivering on our first quarter results. At the same time, we are working broadly to assess the performance and efficiencies across all of our operations as well as administrative functions and we are making good progress; I am pleased with the results so far. Our first quarter results are in line with the expectations we have set out.”